Related Experiment Video
Updated: Jun 29, 2026
09:27
Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
Published on: January 5, 2016
Glucosidase-beta variations and Lewy body disorders
Matthew J Farrer1, Lindsey N Williams, Avi A Algom
1Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA. farrer.matthew@mayo.edu
Parkinsonism & Related Disorders
|October 3, 2008
Summary
Glucosidase-beta mutations are not a major risk factor for Lewy body disorders. This study found few mutations in patients, suggesting limited susceptibility in North America.
Area of Science:
- Neurogenetics
- Neuropathology
- Molecular Biology
Background:
- Lewy body disorders (LBD) are a spectrum of neurodegenerative diseases.
- Previous research suggested a potential link between glucosidase-beta mutations and LBD.
Purpose of the Study:
- To investigate the frequency of glucosidase-beta mutations in neuropathologically confirmed Lewy body disease cases.
- To determine if glucosidase-beta variants contribute to LBD susceptibility.
Main Methods:
- Comprehensive DNA sequencing was performed on 101 neuropathologically defined Lewy body disease cases.
- Genetic data from 99 healthy post-mortem controls were used for comparison.
- Statistical analysis, including odds ratio calculation, was employed.
Main Results:
- A low frequency of glucosidase-beta mutations was observed in LBD cases (3%) compared to controls (1%).
- The odds ratio for mutation carriers was 3.0 (95% CI: 0.3-29, p=0.3), indicating no statistically significant association.
- All identified mutation carriers (n=3/50; 6%) were diagnosed with diffuse Lewy body disease.
Conclusions:
- Glucosidase-beta variants appear to play a limited role in the susceptibility to Lewy body disease.
- Further research may be needed to explore other genetic factors in LBD pathogenesis.
- These findings suggest limited relevance of glucosidase-beta mutations for LBD risk in North America.
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:22Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:27Glucose Transporters
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes: